Moreover, the anti-growth effect of TRIM22, which was observed in subcutaneous xenograft experiments, can be reversed by the upregulation of Smad2, indicating that TRIM22 suppressed gastric cancer progression by blocking the TGF-β/Smad pathway [119]. This evidence concerns the gene SMAD2 and gastric cancer.